Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environmentCAMBRIDGE, Mass., May 02, ...

Viehbacher's pay that year was exceeded only by Jason Robins, the CEO of DraftKings, and Douglas Ingram, president and chief ...

Biogen is addressing profitability concerns and a lack of top-line growth. Read more to see an overview and analysis of BIIB ...

In the preceding three months, 27 analysts have released ratings for Biogen (NASDAQ:BIIB), presenting a wide array of ...

Biogen's Alzheimer therapy, Leqembi, is gaining traction with Q1'24 sales of $19m, nearly tripling Q4 revenues. Read my ...

Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older ...

To be a better neuroscience company, Biogen is going to have to diversify—outside of the therapeutic area that has in recent ...

Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations, as the biotech giant cut costs and its new ...

Biogen on Wednesday reported a first-quarter profit that exceeded estimates as the Cambridge drug maker cut costs and sales ...

Biogen shares gained ground before market open Wednesday, after the company reported first-quarter profit that beat analysts’ ...

While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks—thanks in large ...

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the ...